The Zombie Pattern: How Distressed Companies Drain Before They Fall

Two corporate decisions landed within days of each other in late July 2026, and between them they expose how badly the market reads reinvestment.

On 27 July, Japan's Seven & i Holdings confirmed it had walked away from talks to take a stake in Żabka Group, the largest convenience store operator in Poland. Reporting put the contemplated stake at several tens of a percent and the transaction value in the hundreds of billions of yen. Seven & i's explanation was unusually plain: it could not reach agreement with the seller on terms it considered to be in the interest of its shareholders and other stakeholders. This was not a company without ambition. It is publicly targeting growth from roughly 87,000 stores to 100,000 by 2030, and its European footprint is currently thin — around 360 stores concentrated in the Nordics. Żabka would have been a Central European foothold with 10,000 franchised stores and 27.15bn zlotys ($7.16bn) of revenue in the twelve months to December 2025. Seven & i said Europe remains attractive and it will keep evaluating. Then it declined.

Now the other case. Dawonsys, a KOSDAQ-listed rolling-stock and power-electronics maker, has been suspended from trading since 17 March 2026, received a disclaimer of audit opinion on 23 March, and filed for court rehabilitation on 31 March. In April it was granted roughly a year's improvement period. Then on 5 June the exchange designated it for a substantive listing-eligibility review again — this time because it failed to file litigation-related disclosures on time, drawing 13 penalty points and pushing its one-year cumulative total to 23. Between March and May, eight separate disclosure failures were recorded. It submitted an improvement plan on 26 June, and the exchange set 27 July as the deadline for its review committee to decide between delisting and a further improvement period.

The financial deterioration underneath is severe. FY2025 consolidated revenue fell to ₩112.1bn — roughly a third of the prior year — with an operating loss of ₩120.7bn and a net loss of ₩196.9bn. Total liabilities went from ₩486.8bn at end-2024 to ₩1,131.6bn at end-2025. Accumulated deficit went from ₩67.5bn to ₩846.7bn. By end-2025 equity was fully impaired and quarterly revenue had dropped below ₩300m.

But the sequence matters more than the levels. Between January and March 2026, three contracts were terminated: a ₩220.8bn Korail EMU-150 order equal to 61.7% of recent annual revenue, a ₩113.8bn Sinansan Line order, and a ₩36.0bn Seoul Line 9 order — ₩370.6bn of backlog gone in four months, 3.3x the entire year's revenue. Delay penalties owed to Seoul Metro reportedly reached about ₩75.2bn. Reported production problems included vehicles built roughly 15 tonnes over design weight and test-run schedules revised eight times. And separately, questions were raised about whether advance payments intended for vehicle production were instead directed toward a new headquarters building and toward covering losses elsewhere — a matter under investigation.

What RII is actually reading. The Reinvestment Intensity Index is easy to misread as a capex counter. It is not. It reads the investment gap: the distance between where capital was contractually promised to land and where it demonstrably landed, together with how erratic that landing is quarter to quarter. Under that definition, Seven & i's cancellation is close to a non-event — an explained refusal, with the strategic target left standing. The Korean case is the opposite: capital was deployed, but into an asset that does not produce the revenue the capital was raised against. Deployment is not virtue. Destination is.

Korea parallel. The regulatory architecture has been moving toward exactly this reading. The maximum improvement period available in KOSDAQ substantive reviews has been cut from two years to eighteen months and now to one year, and review stages are being compressed. That trend is an admission that the drain phase — the stretch where a company still trades, still files, still announces, but has stopped converting capital into productive assets — was previously too long. Investors bore that interval.

Academic frame. Jensen (1986), "Agency Costs of Free Cash Flow, Corporate Finance, and Takeovers," American Economic Review 76(2), argued that managers with discretionary cash tend to invest below the cost of capital rather than return it — overinvestment as an agency problem, not a growth signal. Caballero, Hoshi and Kashyap (2008), "Zombie Lending and Depressed Restructuring in Japan," American Economic Review 98(5), showed how firms kept alive without productive reinvestment suppress the performance of healthy competitors around them. Read together: spending is not evidence of health, and prolonged survival is not evidence of viability.

For an individual investor, the practical instrument here is unglamorous. In the Korean case, the disclosure record degraded before the auditor's opinion did — eight filing failures and 23 penalty points preceded the review that now decides the company's listing. Filing hygiene is public, free, and early. So: when a company you hold announces it is deferring investment, what evidence would move you from "prudent" to "depleting"?

Structural observations based on public disclosures and press reporting. Not investment advice.

#RaymondsRisk #RelationalRisk #CorporateGovernance #ReinvestmentRisk #KOSDAQ #CapitalDiscipline